BIOCRYST PHARMACEUTICALS, INC. Payments of Financing Costs
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Payments of Financing Costs of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2025-02-25
- BIOCRYST PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2022-03-31 was $34.00K, a 0.00% change year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2021-03-31 was $34.00K.
- BIOCRYST PHARMACEUTICALS, INC. payments of financing costs for fiscal 2022 was $34.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 12 month |
|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $34.00K 10-K · filed 2025-02-25 | |
| 2022-03-31 | $34.00K 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $34.00K 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |